Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Neurocrit Care. 2018 Oct;29(2):253–263. doi: 10.1007/s12028-018-0535-7

Figure 4. Mannitol and hypertonic saline attenuate nitric oxide synthase (NOS2) expression.

Figure 4

A–D: Double immunolabeling at 48 hours for Iba1 (green) and NOS2 (red), ipsilateral to the ICH (moderate-dose collagenase model), for ICH without treatment (ICH) (A), ICH with mannitol treatment (ICH+Man) (B), and ICH with hypertonic saline treatment (ICH+HTS) (C); merged images are shown in A, right panel, in B, right panel, and in C; the merged images also show nuclear staining with DAPI; the bar graphs show quantification of NOS2 in Iba1+ cells in the four conditions indicated (D); **, P<0.01 for treatments compared to no treatment; n=5/group.